BioTuesdays

Category - Markets

Profound Medical Logo

Paradigm ups Profound Medical PT to $3

Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20. “We see this...

SELLAS Life Sciences Logo

Maxim ups Sellas Life Sciences to buy; PT $13

Maxim Group upgraded Sellas Life Sciences (NASDAQ:SLS) to “buy” from “hold,” with a $13 price target after meeting with Sellas management. The stock closed at $4.79 on March 16. Sellas completed a merger with Galena...

Piper upgrades Nuvectra to OW; PT to $16

Piper Jaffray upgraded Nuvectra (NASDAQ:NVTR) to “overweight” from “neutral” and raised its price target to $16 from $12 after the company reported fourth quarter results. The stock closed at $11.69 on March 15. The...

Volition

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

Motus GI Holdings

Piper starts Motus GI at OW; PT $7

Piper Jaffray initiated coverage of Motus GI Holdings (NASDAQ:MOTS) with an “overweight” rating and $7 price target. The stock closed at $4.98 on March 9. The company’s Pure-Vu device makes the prep regimen for...

Can-Fite

Maxim cuts Can-Fite Biopharma to hold; removes PT

Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...